As congressional investigators dug into the troubled biotech firm ImClone in June, they had a simple but explosive question for Martha Stewart, a friend of former ImClone CEO Samuel Waksal's: Did she receive inside information that prompted her to sell her ImClone stock just a day before the Food and Drug Administration (FDA) rejected ImClone's cancer drug and sent the share price tumbling?
Eager to keep Stewart from testifying at a House Energy and Commerce Committee hearing June 13, sources say, her lawyers agreed to respond in writing. The letter, which arrived the day before the hearing, explained that her $228,000...
To continue reading:
or
Log-In
